Decision Diagnostics Provides Additional Commentary About Its New GenAccord!(TM) Diabetic Test Strip

Decision Diagnostics Corp.

Companies Mentioned:

Primary Exchange: OTC PINK
Under the Symbol: DECN

$0.02

$0.00

15.15%


Decision Diagnostics Provides Additional Commentary About Its New GenAccord!(TM) Diabetic Test Strip

Wednesday, December 20, 2017 9:20 AM

GenAccord!™ Offers Newly Innovative "Either / Or" Technology, Allowing the Test Strip to Work on More Than One Legacy Diabetic Meter

LOS ANGELES, CA / ACCESSWIRE / December 20, 2017 / Decision Diagnostics Corp. (OTC PINK: DECN) is a manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate!™ ("Sunshine") diabetes test strip, the new internationally launched GenSure!™ ("Feather") diabetes test strip, and the clinical trial ready GenChoice!™ "Ladybug" diabetes test strip, as well as three other unique test strips and meters in development, including our panacea strip and meter system the highly innovative GenPrecis! ™.

Today, DECN previews the GenAccord!™ test strip, the company's latest product addition to its suite of blood glucose test strips. GenAccord!™ significantly becomes the company's first derivative product expansion employing the GenPrecis!™ full spread electro-chemistry technology.

Keith Berman, CEO of Decision Diagnostics, commented, "GenAccord!™ is a significant technological advancement. Rather than being limited to a single test meter or family of test meters made by a single legacy manufacturer, GenAccord!™ is adaptive to multiple different generations of meters where the glucose chemistries are similar. Remarkably, this strip works precisely and accurately with new meter technology or with vintage meters. It features the flexibility of functioning with meters made by the same or different legacy manufacturers, regardless of generation or vintage, since many meter and strip systems evolved from the same technology roots. Each GenAccord!™ test strip would operate with two different meter combinations."

Mr. Berman continued, "There are approximately 29 million glucometers in use worldwide. GenAccord!™ could reasonably generate $65 million annually in the traditional Type II marketplaces, and an additional $17 million annually in Type 1, Gestational, and Type 1.5 marketplaces with net profits approaching 20%. GenAccord!™ will initially be compatible with products manufactured by one strong worldwide industry leader, meters and test strip systems currently used by approximately 800,000 diabetics worldwide. This strong worldwide industry player first introduced their legacy meter in 2005, and then followed up with an improved system introduced in 2014. GenAccord!™ will work on both meters and provide the earlier legacy meter with improvements included in the second legacy meter."

Mr. Berman concluded, "GenAccord!™ contributes to our vision of transforming DECN into a legacy technology pioneer and manufacturer. Our engineers were charged with the task of designing a product that will carve a technological gateway to the next decade. GenAccord!™ creation allows us to bridge the technology chasm between fully functioning legacy meters to the current breakthrough meter technologies. GenAccord!™ represents both a direct sale and exclusive private label product opportunity for the company."

ABOUT DECISION DIAGNOSTICS CORP.

Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN's products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.2 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products will shortly compete on a worldwide scale with legacy manufacturers currently selling to 66%+ percent of a $12 billion market.

Forward-Looking Statements:

This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of December 18, 2017 regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.

CONTACT INFORMATION:

Decision Diagnostics Corp.
Keith Berman (805) 446-2973
[email protected]
www.genultimate.com
www.pharmatechdirect.com

SOURCE: Decision Diagnostics Corp.


Subscribe to alerts from Investor Network
SHARE ARTICLE